Our News

John Maraganore Named to Bloomberg 50 List for 2018

December 11, 2018

Alnylam Pharmaceuticals

Alnylam CEO John Maraganore has been named to the Bloomberg 50 list for 2018.  He and Spark Therapeutics CEO Jeff Marrazzo were deemed "the gene medicine revolutionaries" for leading companies that introduced the first groundbreaking genetic treatments derived from the mapping of the human genome.

Click here to read the article on the Bloomberg website.

 

Tags

Leadership, Articles, John Maraganore

Related Content See All News ›
Leadership Leading by Example in Gender Diversity Among Executive Leadership
Leadership Alnylam Named One of Fast Company's Most Innovative Companies for 2023
Leadership Partnering with Nucleate to Support Young Biotech Entrepreneurs

Categories

Content Types

See All News ›
Related Content See All News ›
Leadership Leading by Example in Gender Diversity Among Executive Leadership
Leadership Alnylam Named One of Fast Company's Most Innovative Companies for 2023
Leadership Partnering with Nucleate to Support Young Biotech Entrepreneurs
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site